|

CXCR1/2 Inhibitor SX-682 Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Also known as: SX 682, SX-682, SX682

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • University of Washington2
  • Roswell Park Cancer Institute1

Indications

  • Cancer3
  • Recurrent Lung Non-Small Cell Carcinoma2
  • Stage IV Lung Cancer AJCC v82
  • Metastatic Lung Non-Small Cell Carcinoma2
  • Lung Cancer2

Seattle, Washington2 trials

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Buffalo, New York1 trial

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.